In terms of guidance, the company updated full-year EPS expectations to $3.40 to $3.45, but Eli Lilly still expects revenue in the range of $19.7 billion to $20 billion. There are consensus estimates of $3.28 in EPS on $19.93 billion in revenue.
In terms of its drugs, the company highlighted a few revenues:
- Humalog had $705 million.
- Alimta had $628.5 million.
- Cialis had $566.1 million.
- Forteo had $348.9 million.
- Humlin $316.7 million.
- Cymbalta had $242.9 million.
- Zyprexa had $237.9 million.
- Strattera had $196.9 million.
- Effient had $132.1 million.
- Cyramza had $111.2 million.
- Trajenta had $92.7 million.
- Evista had $58 million.
- Trulicity had $73.7 million.
John C. Lechleiter, Ph.D., chairman, president and CEO, commented on earnings:
We are pleased with our strong third-quarter results, which reflect the ongoing actions we are taking to grow revenue and increase productivity while we are replenishing and advancing our pipeline with an array of new, innovative therapies. Despite headwinds from foreign exchange rates, we are benefiting from recent launches as well as our acquisition of Novartis Animal Health earlier this year.
ALSO READ: The Most Profitable Companies in the World
He added:
This quarter, we had higher sales volume for several key products, including recently launched Cyramza and Trulicity. We also launched several new products in various global markets, including Synjardy in the U.S. for type 2 diabetes. Promising pipeline momentum continued with encouraging news for baricitinib and abemaciclib, while Jardiance reported positive cardiovascular outcomes. Finally, we continued to create new collaborations and pursue smaller-scale acquisitions to bolster our pipeline and our product portfolio.
Shares of Eli Lilly were down fractionally at $76.68 Thursday morning. It has a consensus analyst price target of $95.79 and a 52-week trading range of $63.41 to $92.85.
Top Gaining Stocks
Top Losing Stocks